Pluvicto extends disease control in advanced hormone-sensitive prostate cancer

/in , , /by

The Phase III PSMAddition trial presented at the 2025 European Society for Medical Oncology Congress marks a meaningful advance in the treatment of prostate cancer that still responds to hormonal therapy but has already spread to distant sites. In this study, patients with prostate-specific membrane antigen–positive metastatic hormone-sensitive prostate cancer received the radioligand therapy Pluvicto […]

Read more

Rapid Genome Sequencing Redefines Clinical Readiness

/in /by

A collaboration between Broad Clinical Labs, Roche Sequencing Solutions, and Boston Children’s Hospital has set a Guinness World Record for sequencing and analyzing a whole human genome in under four hours. The record, confirmed this month and documented in the New England Journal of Medicine, demonstrates that complete genomic workflows can be completed in less […]

Read more

Phase 1/2 AlphaBet Trial: Promising Combination of Lutetium-177 PSMA-I&T and Radium-223 in Advanced Prostate Cancer

/in , , , /by

A novel therapeutic approach combining lutetium-177 177Lu-PSMA-I&T and radium-223 (223Ra) shows encouraging results for men with metastatic castration-resistant prostate cancer (mCRPC), as demonstrated in the recently reported AlphaBet trial published in The Lancet Oncology in October 2025. This phase 1/2 AlphaBet study is the first to evaluate the safety, feasibility, and preliminary efficacy of the […]

Read more

Real-World ARON-3 Data Highlight the Advantage of Triplet Therapy in High-Volume mHSPC

/in /by

At the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin,  pivotal real-world data from the international ARON-3 study were revealed, advancing treatment insights for high-volume metastatic hormone-sensitive prostate cancer (mHSPC) with bone metastases. The ARON-3 study evaluated 841 patients receiving either doublet therapy, combining androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors […]

Read more

ARASAFE Trial Offers Safer Docetaxel-Darolutamide-ADT Regimen for mHSPC

/in , , /by

Recent data presented at the 2025 European Society for Medical Oncology (ESMO) Congress reveal a promising new treatment schedule for patients with metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 ARASAFE trial evaluated an alternative docetaxel dosing regimen combined with darolutamide and androgen deprivation therapy (ADT), showing significant reductions in severe toxicities while maintaining effective […]

Read more

Phase 1/2 PETRANHA Trial Update: Promising Results Reported at ESMO 2025

/in , , , /by

At the 2025 ESMO Congress, new data from the phase 1/2 PETRANHA trial introduced saruparib (AZD5305), a highly selective PARP1 inhibitor, as a potentially safer and more effective therapeutic partner for androgen receptor pathway inhibitors (ARPIs) in metastatic prostate cancer. The results highlighted a strong efficacy signal in castration-sensitive disease and ARPI-naïve castration-resistant settings, while […]

Read more

AI Model Bridges Cellular Biology and Machine Reasoning

/in /by

A collaboration between Yale University and Google DeepMind has led to a rare scientific milestone: an artificial intelligence system that not only analyzed biological data but also generated and experimentally validated a new hypothesis for cancer treatment. Announced on October 15, 2025, the 27‑billion‑parameter foundation model, called Cell2Sentence‑Scale 27B, was developed to interpret single‑cell RNA […]

Read more

Two-Pronged Drug Combination for Advanced Prostate Cancer: Fadraciclib Plus Ipatasertib (or Capivasertib)

/in /by

Scientists at The Institute of Cancer Research in London have identified a combination therapy that may benefit up to 40 percent of men with advanced prostate cancer, particularly those whose tumors have become resistant to hormone therapies. This approach targets two proteins essential for cancer cell survival: MCL1 and AKT. Direct inhibition of MCL1 has […]

Read more